Flow cytometry analysis of tumor infiltrating T cells was consistent with the scRNA-Seq data, confirming a significantly higher number of IL-17A expressing T cells in sensitive tumors than resistant tumors (1.83%, 0.85% respectively, p-value=0.0016) (Figures 5F–H) with γδ T cells constituting the majority of the IL-17A expressing cells (1.36%, 0.51% respectively) regardless of tumor chemotherapeutic response (Figure 5I). This evidence concerns the gene IL17A and neoplasm.